Urea compounds, compositions, and methods for treating asthma and parkinson's disease
Urea compounds with specific ring structures address the limitations of current asthma and Parkinson’s disease treatments by reducing IL-1 beta expression and offering a potential alternative to existing therapies with fewer side effects.
Patent Information
- Application Number
- PCT/IB2024/055345
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-02
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
Current treatments for asthma and Parkinson’s disease are inadequate, with glucocorticoids for asthma causing side effects and L-DOPA for Parkinson’s leading to adverse effects and not halting disease progression.
Development of urea compounds with specific aromatic or heteroaromatic rings, optionally substituted with certain groups, for use in pharmaceutical compositions to treat asthma and Parkinson’s disease, administered orally or via other routes.
The compounds effectively reduce IL-1 beta expression in THP-1 cells, indicating potential for treating asthma, and show promise in managing Parkinson’s disease symptoms without the severe side effects of existing treatments.
Smart Images

Figure IB2024055345_05122024_PF_FP_ABST
Abstract
Description
UREA COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ASTHMA AND PARKINSON’S DISEASE
[0001] This disclosure relates to compounds and their use for treating asthma. This disclosure also relates to compounds and their use for treating Parkinson’s disease.
[0002] Asthma is a chronic inflammatory disease of the lower respiratory tract characterized by airway hyperresponsiveness and mucous obstruction. Bronchial asthma is the most common chronic disease affecting children and young adults. There is strong evidence for a genetic component in asthma (Bleecker et al., Am. J. Respir. Crit. Care. Med., 156: SI 13-6 (1997); Kauffmann et al., Chest, 121 (3 Supp.): 27S (2002)). Multiple environmental factors are also known to modulate the clinical expression of asthma as well as the asthma-associated phenotypes: bronchial hyperresponsiveness, atrophy and elevated IgE (Koppelman et al., Eur. Resp. J., 13: 2-4 (1999); Cookson, Nature, 25: B5-11 (1999); Holloway, Clin. Exp. Allergy, 29: 1023-1032 (1999)).
[0003] Pharmacologic analogues of cortisol (e.g., prednisone) have been used clinically since 1948 and remain the standard of care for the treatment of a variety of inflammatory diseases including asthma. These glucocorticoids (GC) reduce pathological inflammation that is central to asthma, and they are thought to control clinical asthma symptoms through their antiinflammatory effects (Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin. Immunol. 2007, 120:S94-138). There remains a need for improved methods for treating asthma.
[0004] Parkinson’s disease is a disturbance of voluntary movement in which muscles become stiff and sluggish, movement becomes clumsy and difficult and uncontrollable rhythmic twitching of groups of muscles produces characteristic shaking or tremor. The condition is believed to be caused by a degeneration of pre-synaptic dopaminergic neurones in the brain. The absence of adequate release of the chemical transmitter dopamine during neuronal activity thereby leads to the Parkinsonian symptomatology.
[0005] The most widely used treatment for Parkinsonism is administration of L-DOPA, a precursor of dopamine which acts indirectly by replacing the missing dopamine. However, disadvantages are associated with the use of L-DOPA, for example, patients often suffer from side-effects such as dyskinesia and on-off effects, and it is necessary to administer L DOPA in conjunction with a peripheral dopa-decarboxylase inhibitor such as carbidopa or benzaseride. These inhibitors prevent the peripheral degradation of levodopa to dopamine, thus enablingmore drug to enter the brain and limiting peripheral side-effects. Such treatment improves quality of life for patients but does not halt disease progression. Furthermore, such treatment is associated with a number of adverse effects, including nausea, vomiting, abdominal distension and psychiatric side-effects (for example, toxic confusional state, paranoia, and hallucinations). There continues to be a need for improved treatments for Parkinson’s disease.SUMMARY
[0006] This disclosure relates to compounds of the following structure:or a pharmaceutically acceptable salt thereof, wherein: n is 0, 1, or 2; A is a 5-6 membered aromatic or heteroaromatic ring, wherein the heteroaromatic ring contains 1-2 nitrogen atoms at any position, and A is optionally independently substituted at any position with up to 3 substituents selected from the group consisting of C1-C4 straight or branched alkyl or alkoxy, phenoxy, -NO2, -CF3, -CN, -F, -Cl, or -Br.
[0007] In some embodiments n is 0 or 1; A is phenyl, anthryl, or pyrazolyl; and A is optionally independently substituted at any position with up to 3 substituents selected from the group consisting of C1-C3 straight or branched alkyl, phenoxy, -NO2, -CF3, -CN, -F, or -Br.
[0008] In other embodiments n is 1; A is phenyl; and A is optionally independently substituted at any position with C1-C3 straight or branched alkyl, phenoxy, or -NO2. In particular embodiments, the compound can be
[0009] In other embodiments n is 0; A is phenyl, naphthyl, or IH-pyrazolyl; and A is optionally independently substituted at any 1 or 2 positions with F, CF3, CN, Br, or -NO2. In particular embodiments, the compound can be
[0010] In other embodiments, n is 0 or 1; and A is phenyl, thiophenyl, pyrimidinyl, pyridyl, naphthyl, isoquinolinyl, imidazolyl, benzimidazolyl, benzofuranyl, or benzoxazolyl, wherein A is optionally independently substituted at any position with C 1-C3 straight or branched alkyl, phenyl, halide, -OCF3, -SCF3, -CF3, cyano, -CO2CH3, -CO2CH2CH3, or -OCH3.
[0011] In particular embodiments, the compound can be2288 23512369
[0012] In other aspects of this disclosure are pharmaceutical compositions, comprising an effective amount of any of the compounds described above and a pharmaceutically acceptable carrier.
[0013] In other aspects of this disclosure are methods of treating asthma or Parkinson’s disease, comprising administering a pharamceutically effective amount of any of the compounds or compositions described above to a subject in need thereof.BRIEF DESCRIPTION OF THE FIGURES
[0014] FIGS. 1A-1C, 2A-2C, 3A-3C, 4A-4C, 5A-5B, 6A-6B, 7A-7B, 8A-8B, and 9A-9B are spectral data for compounds 2301-2309.
[0015] FIGS. 10A-10C, 11A-11C, 12A-12C, 13A-13C, 14A-14C, 15A-15B, 16A-16B, and 17A-17B are spectral data for compounds 2285-2292.
[0016] FIGS. 18A and 18B show the effect of compounds 2289 - 2309 on expression of IL-1 beta in THP-1 cells by ELISA system.
[0017] FIG. 19 shows the effect of the derivatives on the cell viability.
[0018] FIGS. 20A and 20B show the effect of the compounds 2348 - 2377 on expression of IL-1 beta in THP-1 cells by ELISA system.
[0019] FIG. 21 shows the effect of the compounds 2351, 2352, 2356, 2359, 2360, 2366, 2368, 2373, 2375, 2376, 2377 on expression of IL-lbeta in THP-1 cell by ELISA system.DETAILED DESCRIPTION
[0020] This disclosure relates to compounds of the following structure:or a pharmaceutically acceptable salt thereof, wherein: n is 0, 1, or 2; A is a 5-6 membered aromatic or heteroaromatic ring, wherein the heteroaromatic ring contains 1-2 nitrogen atoms at any position, and A is optionally independently substituted at any position with up to 3 substituents selected from the group consisting of C1-C4 straight or branched alkyl or alkoxy, phenoxy, -NO2, -CF3, -CN, -F, -Cl, or -Br.
[0021] In some embodiments n is 0 or 1; A is phenyl, anthryl, or pyrazolyl; and A is optionally independently substituted at any position with up to 3 substituents selected from the group consisting of C1-C3 straight or branched alkyl, phenoxy, -NO2, -CF3, -CN, -F, or -Br.
[0022] In other embodiments n is 1; A is phenyl; and A is optionally independently substituted at any position with C1-C3 straight or branched alkyl, phenoxy, or -NO2. In particular embodiments, the compound can be
[0023] In other embodiments n is 0; A is phenyl, naphthyl, or IH-pyrazolyl; and A is optionally independently substituted at any 1 or 2 positions with F, CF3, CN, Br, or -NO2. In particular embodiments, the compound can be
[0024] In other embodiments, n is 0 or 1; and A is phenyl, thiophenyl, pyrimidinyl, pyridyl, naphthyl, isoquinolinyl, imidazolyl, benzimidazolyl, benzofuranyl, or benzoxazolyl, wherein A is optionally independently substituted at any position with C 1-C3 straight or branched alkyl, phenyl, halide, -OCF3, -SCF3, -CF3, cyano, -CO2CH3, -CO2CH2CH3, or -OCH3.
[0025] In particular embodiments, the compound can be2288 2351
[0026] In other aspects of this disclosure are pharmaceutical compositions, comprising an effective amount of any of the compounds described above and a pharmaceutically acceptable carrier.
[0027] In other aspects of this disclosure are methods of treating asthma or Parkinson’s disease, comprising administering an effective amount of any of the compounds or compositions described above to a subject in need thereof.
[0028] Asthma can be but is not limited to allergen-induced asthma, viral-induced asthma, cold-induced asthma, pollution-induced asthma and / or exercise-induced asthma.
[0029] In some embodiments of the method of treating asthma or Parkinson’s disease, the compositions are administered orally to the subject. In some embodiments of the method oftreating asthma or Parkinson’s disease, the compositions comprise 0.001 mg to 100 mg of each of the compound per kg of the subject’s body weight.
[0030] As used herein, “pharmaceutically acceptable” means molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or to a human, as appropriate.
[0031] The term, “pharmaceutically acceptable carrier” includes one or more inert excipients, which include starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, disintegrating agents, and the like, and any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. “Pharmaceutically acceptable excipient” also encompasses controlled release means.
[0032] Whether a particular excipient is suitable for a pharmaceutical composition or a dosage form depends on various factors well known in the art, including methods of formulating preparations to be administered to a patient, but is not limited thereto. For example, dosage forms for oral administration such as tablets can include an excipient not suitable for use in preparations for non-oral administration.
[0033] The pharmaceutical compositions can include those suitable for aerosol, pulmonary, inhalation, oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration. The most suitable route can depend upon the condition and disorder of the recipient. The compositions can conveniently be presented in unit dosage form and can be prepared by any of the methods well known in the art of pharmacy. In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired composition.
[0034] Compositions of the present disclosure can also optionally include other therapeutic ingredients, anti-caking agents, preservatives, sweetening agents, colorants, flavors, desiccants, plasticizers, dyes, and the like. Any such optional ingredient must, of course, be compatible with the compound of the disclosure to insure the stability of the composition.
[0035] In addition to salt forms, the present disclosure provides compounds that are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the disclosure. Additionally, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the disclosure when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they can be easier to administer than the parent drug. They can, for example, be bioavailable by oral administration whereas the parent drug is not. The prodrug can also have improved solubility in pharmaceutical compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound of the disclosure which is administered as an ester (the “prodrug”), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound of the disclosure.
[0036] Certain compounds of the present disclosure can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the disclosure. Certain compounds of the disclosure can exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the disclosure and are intended to be within the scope of the disclosure.EXAMPLES
[0037] General method for synthesis of compounds
[0038] To a solution of 4-chlorophenyl isocyanate 0.5 g (3.25 mmol) in toluene (5 ml) at room temperature, the amine (3.25 mmol) was added. Immediate formation of the urea was noted as evident by the formation of solid (in the case of benzyl amines). The resulting reaction was refluxed for 1 hr. The obtained solid was filtered, washed with ether, and dried.
[0039] Example 1: Compound 2301: l-(4-chlorophenyl)-3-(4-nitrobenzyl)urea
[0040] Following the procedure mentioned above, compound 2301 was prepared using 4- nitrobenzylamine hydrochloride (0.61 g, 3.25 mmol) as the amine.
[0041] 1H NMR (500 MHz, DMSO) 6 8.89 (s, 1H), 8.21 (d, J = 10 Hz, 2H), 7.56 (d, J = 5 Hz, 2H), 7.44 (d, J = 10 Hz, 2H), 7.27 (d, J = 5 Hz, 2H), 6.86 (t, J = 5 Hz, 1H), 4.43 (d, J = 5 Hz, 2H).
[0042] 13C NMR (126 MHz, DMSO) 6 155.15, 152.38, 151.03, 150.96, 139.35, 134.68, 133.41, 128.50, 128.00, 123.52, 119.31, 42.37.
[0043] [M+H]+ 306.05.
[0044] Yield: 200 mg, 20%
[0045] Example 2: Compound 2302: l-(4-chlorophenyl)-3-(4-phenoxybenzyl)urea
[0046] Following the procedure mentioned above, compound 2302 was prepared using 4- phenoxybenzylamine (0.65 g, 3.25 mmol) as the amine.
[0047] 1H NMR (500 MHz, DMSO) 6 8.86 (s, 1H), 8.71 (s, 1H), 7.48 (d, J = 10 Hz, 2H), 7.44 (d, J = 5 Hz, 1H), 7.37 (t, J = 5 Hz, 2H)), 7.33 - 7.31 (m, 4H), 7.26 (d, J = 10 Hz, 1H), 7.11 (t, J = 5 Hz, 1H), 6.98 (m, 3H), 6.66 (t, J = 5 Hz, 1H), 4.28 (d, J = 5Hz, 2H).
[0048] 13C NMR (126 MHz, DMSO) 6 156.98, 155.30, 152.36, 139.48, 138.57, 135.51, 130.03, 128.93, 128.66, 128.49, 125.50, 124.55, 123.25, 119.84, 119.19, 118.80, 118.28, 115.17, 42.20.
[0049] [M+H]+ 353.09
[0050] Yield: 170 mg, 14.9%
[0051] Example 3: Compound 2302: l-(4-chlorophenyl)-3-(4-phenoxybenzyl)urea
[0052] Following the procedure mentioned above, compound 2303 was prepared using 4- isopropylbenzylamine (0.48 g, 3.25 mmol) as the amine.
[0053] 1H NMR (500 MHz, DMSO) 6 8.86 (s, 1H), 8.67 (s, 1H), 7.48 (d, J = 10 Hz, 1H), 7.43 (d, J = 5 Hz, 2H), 7.32 (d, J = 10 Hz, 1H), 7.25 (d, J = 10 Hz, 2H), 7.22 - 7.16 (m, 3H), 6.61 (t, J = 5 Hz, 1H), 4.24 (d, J = 10 Hz, 2H), 2.85 (septet, J = 10 Hz, 1H), 1.18 (s, 3H), 1.16 (s, 3H).
[0054] 13C NMR (126 MHz, DMSO) 6 155.05, 146.97, 139.51, 138.58, 137.58, 128.67, 128.50, 127.27, 126.23, 125.53, 124.53, 119.86, 119.16, 42.57, 33.17, 24.00
[0055] [M+H]+ 303.11
[0056] Yield: 140 mg, 14.2%
[0057] Example 4: Compound 2304: l-(4-chlorophenyl)-3-cyclohexylurea
[0058] Following the procedure mentioned above, compound 2304 was prepared using cyclohexylamine (0.32 g, 3.25 mmol) as the amine.
[0059] 1H NMR (500 MHz, DMSO) 6 8.43 (s, 1H), 7.39 (d, J = 10 Hz, 2H), 7.24 (d, J = 10 Hz, 2H), 6.10 (d, J = 10 Hz, 1H), 3.45 - 3.40 (m, 1H), 1.79 - 1.78 (m, 2H), 1.65 - 1.63 (m, 2H), 1.54 - 1.53 (m, 1H), 1.31 - 1.18 (m, 2H), 1.18 - 1.14 (m, 3H).
[0060] 13C NMR (126 MHz, DMSO) 6 159.40, 144.74, 139.79, 133.64, 130.64, 129.45, 124.09, 120.32, 52.79, 38.09, 30.40, 29.54 .
[0061] [M+H]+ 253.10
[0062] Yield: 60 mg, 12.5%
[0063] Example 5: Compound 2305: l-(4-chlorophenyl)-3-cyclopentylurea
[0064] Following the procedure mentioned above, LMT-2305 was prepared using cyclopentylamine (0.27 g, 3.25 mmol) as the amine.
[0065] 1H NMR (500 MHz, DMSO) 6 8.38 (s, 1H), 7.39 (d, J = 10 Hz, 2H), 7.24 (d, J = 10 Hz, 2H), 6.19 (d, J = 5 Hz, 1H), 3.93 - 3.89 (m, 1H), 1.85 - 1.79 (m, 2H), 1.63 -1.49 (m, 4H), 1.38 - 1.32 (m, 2H).
[0066] 13C NMR (126 MHz, DMSO) 6 154.62, 139.55, 128.47, 124.31, 118.96, 50.89, 32.79, 23.15.
[0067] Yield: 60 mg, 12.9%
[0068] Example 6: Compound 2306: N-(4-chlorophenyl)-4-methylpiperazine-l- carboxamide
[0069] Following the procedure mentioned above, compound 2306 was prepared using 1- methyl piperazine (0.32 g, 3.25 mmol) as the amine.
[0070] 1H NMR (500 MHz, DMSO) 6 8.62 (s, 1H), 7.48 (d, J = 10 Hz, 2H), 7.26 (d, J = 10 Hz, 2H), 3.42 (t, 4H), 2.30 (t, 4H), 2.19 (s, 3H).
[0071] 13C NMR (126 MHz, DMSO) 6 154.74, 139.59, 128.15, 125.20, 120.93, 54.46, 45.74, 43.61.
[0072] Yield: 210 mg, 25.6%
[0073] Example 7: Compound 2307: Ethyl 4-((4-chlorophenyl)carbamoyl) piperazine-1- carboxylate
[0074] Following the procedure mentioned above, compound 2307 was prepared using ethyl piperazine- 1 -carboxylate (0.51 g, 3.25 mmol) as the amine.
[0075] 1H NMR (500 MHz, DMSO) 6 8.70 (s, 1H), 7.46 (d, J =10 Hz, 2H), 7.26 (d, J = 10 Hz, 2H), 4.04 (q, J = 5 Hz, 2H), 3.33 (s, 9H), 1.18 (t, J = 5 Hz, 3H).
[0076] 13C NMR (126 MHz, DMSO) 6 154.72, 154.65, 139.47, 128.21, 125.37, 121.00, 60.92, 43.47, 14.61.
[0077] Yield: 150 mg, 14.8%
[0078] Example 8: Compound 2308: l-(4-chlorophenyl)-3-pentylurea
[0079] Following the procedure mentioned above, compound 2308 was prepared using n- pentylamine (0.28 g, 3.25 mmol) as the amine.
[0080] 1H NMR (500 MHz, DMSO) 6 8.53 (s, 1H), 7.40 (d, J = 10 Hz, 2H), 7.24 (d, J = 10 Hz, 2H), 6.15 (t, J = 5 Hz, 1H), 3.07 - 3.03 (m, 2H), 1.44 - 1.39 (m, 2H), 1.31 - 1.24 (m, 4H), 0.87 (t, J = 5 Hz, 3H)
[0081] 13C NMR (126 MHz, DMSO) 6 155.02, 139.63, 128.45, 124.30, 119.01, 29.41, 28.60, 21.91, 13.99.
[0082] Yield: 300 mg, 38.4%
[0083] Example 9: Compound 2309: l-(tert-butyl)-3-(4-chlorophenyl)urea
[0084] Following the procedure mentioned above, compound 2309 was prepared using t- butylamine (0.24 g, 3.25 mmol) as the amine.
[0085] 1H NMR (500 MHz, DMSO) 6 8.36 (s, 1H), 7.36 7.23 (d, J = 10 Hz, 2H), 7.23 (d, J = 10 Hz, 2H), 6.0 (s, 1H), 1.28 (s, 9H).
[0086] 13C NMR (126 MHz, DMSO) 6 154.18, 139.63, 128.45, 124.14, 118.81, 49.48, 28.97.
[0087] Yield: 250 mg, 34.2%
[0088] Example 10
[0089] To assess whether IPS-07 guanyl urea derivatives inhibits the expression of IL-1 beta, which play a critical role in asthma pathology, ELISA for IL-1 beta expression in THP-derived macrophage cells was employed. Compounds 2301, 2302, 2303, 2368, 2376, and 2377 (see Table below) most significantly reduced the expression levels of IL-1 beta in THP-derived macrophage cells induced by LPS and ATP (see FIGs 18A and 18C). This data indicates applicability for treating asthma.Code No. Structure Code No. Structure2301 23762302 2377_2303 AV('2368
[0090] To examine the survival rate for THP-1 cells treated with guanyl urea derivatives, an in vitro cell viability assay was performed using MTT. There was little or no effect on the viability when the cells were induced by LPS and ATP (see FIG. 18B).
[0091] Materials
[0092] Streptavidin was purchased from Sigma-Aldrich (St. Louis, Missouri, USA), anti- EML4 polyclonal antibody was customized at AbClon Inc. (Seoul, South Korea). Total Exosome Isolation kit and Total Exosome RNA & Protein Isolation Kit were purchased fromInvitrogen (Carlsbad, California, USA). Cy5-conjugated streptavidin was purchased from GE Healthcare (Chicago, Illinois, USA).
[0093] In Vitro Cell Viability Assay
[0094] THP-1 cells (lxl03 / well) were seeded on a 96-well plate for 16 hrs. After starvation for 24 hrs., the cells were pretreated with LPS or IL- lb for 4 hrs. The cells were then treated with IPS-07004 for 24 hrs in a dose-dependent manner. After 48 hr-incubation, MTT [3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] solution (5 mg / ml) was added to each well in an amount of 1 / 10 of total volume, and the cells were incubated for 2 hrs at 37°C.
[0095] Enzyme-linked Immunosorbent Assay (ELISA) of IL-1 beta
[0096] THP-1 cells (5X106 / well) were seeded on a 96-well plate for 16 hrs. After treatment of Phorbol 12-myristate 13-acetate (100 ng / ml) for 48 hrs at 37°C in a CO2 incubator, the cells were administered with IPS-07 series or MCC950 as a positive control for 24 hrs. And then LPS(10 ng / ml) was treated to the cells for 150 min followed by ATP(1 mM) for 30 min. Level of IL-1 beta in media were analyzed using Human IL-1 beta / IL-lF2 DuoSet ELISA kit in accordance with the manufacturer’s specification (R&D systems, Minneapolis, MN, USA).
[0097] Those skilled in the art will understand that this invention can be embodied in many different forms and should not be construed as limited to the embodiments set forth in this application. Rather, these embodiments are provided so that this disclosure will fully convey the invention to those skilled in the art. Many modifications and other embodiments of the invention will come to mind in one skilled in the art to which this invention pertains having the benefit of the teachings presented herein.
[0098] All of the various aspects, embodiments, and options described herein can be combined in any and all variations.
[0099] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.
Claims
WHAT IS CLAIMED IS:
1. A compound of the following structure:or a pharmaceutically acceptable salt thereof, wherein: n is 0, 1, or 2;A is a 5-6 membered aromatic or hetero aromatic ring, wherein: the heteroaromatic ring contains 1-2 nitrogen atoms at any position, andA is optionally independently substituted at any position with up to 3 substituents selected from the group consisting of C1-C4 straight or branched alkyl or alkoxy, phenoxy, -NO2, -CF3, -CN, -F, -Cl, or -Br.
2. A compound according to claim 1, wherein: n is 0 or 1 ;A is phenyl, anthryl, or pyrazolyl; andA is optionally independently substituted at any position with up to 3 substituents selected from the group consisting of C1-C3 straight or branched alkyl, phenoxy, -NO2, -CF3, -CN, -F, or - Br.
3. A compound according to claim 1, wherein: n is 1;A is phenyl; andA is optionally independently substituted at any position with C 1-C3 straight or branched alkyl, phenoxy, or -NO2.
4. A compound according to claim 3, wherein the compound is:
5. A compound according to claim 1, wherein: n is 0;A is phenyl, naphthyl, or IH-pyrazolyl; andA is optionally independently substituted at any 1 or 2 positions with F, CF3, CN, Br, or -NO2.
6. A compound according to claim 5, wherein the compound is:
7. A compound of the following structure:or a pharmaceutically acceptable salt thereof, wherein: n is 0 or 1 ; andA is phenyl, thiophenyl, pyrimidinyl, pyridyl, naphthyl, isoquinolinyl, imidazolyl, benzimidazolyl, benzofuranyl, or benzoxazolyl, wherein A is optionally independently substituted at any position with C1-C3 straight or branched alkyl, phenyl, halide, -OCF3, -SCF3, -CF3, cyano, -CO2CH3, -CO2CH2CH3, or -OCH3.
8. A compound according to claim 3, wherein the compound is:2364 23652376 2377.
9. A pharmaceutical composition, comprising an effective amount of a compound according to any of the preceding claims and a pharmaceutically acceptable carrier.
10. A method of treating asthma or Parkinson’s disease, comprising administering a pharamceutically effective amount of a compound or composition according to any of the preceding claims to a subject in need thereof.
Citation Information
Patent Citations
Substituted benzamide derivatives
KR1020120110123A
ARYL urea derivatives for treating obesity
WO2006018662A2
Diaryl ureas as CB1 antagonists
WO2006049941A2
Compositions and methods comprising proteinase activated receptor antagonists
WO2007076055A2
Urea derivatives as CB1 allosteric modulators
WO2020264176A1
